Orient Europharma (Taiwan) Today
| 4120 Stock | TWD 47.80 0.40 0.83% |
Performance0 of 100
| Odds Of DistressOver 63
|
Orient Europharma is selling for under 47.80 as of the 2nd of January 2025; that is 0.83 percent decrease since the beginning of the trading day. The stock's lowest day price was 47.8. Orient Europharma has more than 63 % chance of experiencing financial distress in the next few years of operation. It also generated negative returns for investors over the last 90 days. The performance scores are derived for the period starting the 3rd of December 2024 and ending today, the 2nd of January 2025. Click here to learn more.
Moving against Orient Stock
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
Orient Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Orient Europharma's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Orient Europharma or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| Business Concentration | Drug Manufacturers-Specialty & Generic, Healthcare (View all Sectors) |
Orient Europharma Co (4120) is traded on Taiwan OTC Exchange in Taiwan and employs 21 people. The company currently falls under 'Mid-Cap' category with a current market capitalization of 3.13 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Orient Europharma's market, we take the total number of its shares issued and multiply it by Orient Europharma's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Orient Europharma operates under Healthcare sector and is part of Drug Manufacturers-Specialty & Generic industry. The entity has 86.75 M outstanding shares.
Orient Europharma generates positive cash flow from operations, but has no cash available
Check Orient Europharma Probability Of Bankruptcy
Ownership AllocationOrient Europharma owns a total of 86.75 Million outstanding shares. Orient Europharma holds majority of its outstanding shares owned by insiders. An insider is usually defined as a corporate executive, director, member of the board or institutional investor who own at least 10% of the company's outstanding shares. 65.1 pct. of Orient Europharma outstanding shares that are owned by insiders implies they have been buying or selling the stock in recent months in anticipation of some upcoming event. Please note that no matter how many assets the company maintains, if the real value of the company is less than the current market value, you may not be able to make money on it.
Check Orient Ownership Details
Orient Europharma Risk Profiles
Although Orient Europharma's alpha and beta are two of the key measurements used to evaluate Orient Europharma's performance over the market, the standard measures of volatility play an important role as well.
| Mean Deviation | 0.9817 | |||
| Standard Deviation | 1.95 | |||
| Variance | 3.79 | |||
| Risk Adjusted Performance | (0.02) |
Orient Stock Against Markets
Be your own money manager
Our tools can tell you how much better you can do entering a position in Orient Europharma without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Money Flow Index Now
Money Flow IndexDetermine momentum by analyzing Money Flow Index and other technical indicators |
| All Next | Launch Module |
Orient Europharma Corporate Management
Elected by the shareholders, the Orient Europharma's board of directors comprises two types of representatives: Orient Europharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Orient. The board's role is to monitor Orient Europharma's management team and ensure that shareholders' interests are well served. Orient Europharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Orient Europharma's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Liann Lai | Director Division | Profile | |
| Jack Wu | Director | Profile | |
| Phoebe Lee | Chief Officer | Profile | |
| Peter Tsai | CEO Chairman | Profile |
Additional Tools for Orient Stock Analysis
When running Orient Europharma's price analysis, check to measure Orient Europharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Orient Europharma is operating at the current time. Most of Orient Europharma's value examination focuses on studying past and present price action to predict the probability of Orient Europharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Orient Europharma's price. Additionally, you may evaluate how the addition of Orient Europharma to your portfolios can decrease your overall portfolio volatility.